Today, Rare Revolution Magazine launched its summer issue dedicated to diversity, equity and inclusion in rare disease. The issue explores ways that rare disease patient advocacy organizations, individuals and industry are working to advance health equity. Articles include conversations with members of the rare community about race, gender, sexual identity, age bias, access to clinical trials and therapy. Travere is proud to collaborate with Rare Revolution Magazine on this issue.
Ten years after being diagnosed with IgA nephropathy, a rare kidney disease, Stuart’s kidney function had depleted significantly. Today, after a lifesaving kidney donation from his wife, Stuart gives back to the kidney community through advocacy
July 1, 2021 — In its July issue published today, Life Science Leader Magazine featured our president and CEO Eric Dube. The feature piece, “How a First-Time CEO Transformed Retrophin Into Travere Therapeutics”, highlights Eric’s inspirational leadership journey, why Eric decided to join the company, his first 100 days as a new CEO, and the company’s transition from Retrophin to Travere Therapeutics.
https://travere.com/wp-content/uploads/21_07_Cover_lg.jpg698530superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2021-07-01 06:12:052021-07-01 06:19:28In the News: Our president and CEO Eric Dube featured in Life Science Leader Magazine
SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced completion of patient enrollment in the Phase 3 PROTECT Study. The pivotal PROTECT Study is evaluating the safety and efficacy of sparsentan for the treatment of IgA nephropathy (IgAN), a rare kidney disorder that often progresses to end-stage kidney disease (ESKD). Topline efficacy data from the interim 36-week proteinuria endpoint analysis are expected in August 2021.
https://travere.com/wp-content/uploads/Retrophin_SoloMark_FullColor_RGB-300-1.png200200superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2021-06-02 15:18:072021-06-02 15:20:46Travere Therapeutics Completes Enrollment in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
https://travere.com/wp-content/uploads/Retrophin_SoloMark_FullColor_RGB-300-1.png200200superadminhttps://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.pngsuperadmin2021-05-25 04:25:592021-05-26 08:41:10Travere Therapeutics Provides Regulatory Update on Sparsentan Development Program for Focal Segmental Glomerulosclerosis